Bavarian Nordic Appoints James B. Breitmeyer as Executive Vice President and Divison President of its Cancer Vaccine Division

Fri Feb 8, 2013 2:01am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link below:

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130208:nHUGcW2h


KVISTGAARD, Denmark - February 8, 2013 - Bavarian Nordic A/S (OMX: BAVA) announced today that it
has appointed James B. Breitmeyer, M.D., Ph.D. to the position of Executive Vice President and
Division President of its Cancer Vaccine division.

"We are pleased to welcome Dr. Breitmeyer to our executive management team," commented Anders
Hedegaard, President and CEO of Bavarian Nordic. "We believe that his long executive career in the
pharmaceutical industry combined with his solid oncology expertise will provide the perfect
leadership for our cancer vaccine division. He will apply more than two decades of clinical
development experience from research through commercialization to the advancement of our cancer
immunotherapy candidates, in particular PROSTVAC(R), which is currently in Phase 3 development."

"I am very enthusiastic about joining Bavarian Nordic at this exciting time," said James B.
Breitmeyer, M.D., Ph.D. "Immunotherapy of cancer is a career-long interest of mine, and I believe
PROSTVAC(R) represents a state-of-the art approach, and a potentially improved treatment for
patients suffering from advanced prostate cancer. I am looking forward to leading the development
of this promising product candidate successfully through Phase 3 on its path towards
commercialization."

Dr. Breitmeyer served as Executive Vice President of Development and Chief Medical Officer of
Cadence Pharmaceuticals Inc. from 2006 to 2012. From 2001 to 2006, he served as Chief Medical
Officer of Applied Molecular Evolution Inc., a wholly-owned subsidiary of Eli Lilly and Co. From
2000 to 2001, Dr. Breitmeyer served as President and Chief Executive Officer of the Harvard
Clinical Research Institute. From 1991 to 2000, he held a variety of positions at Serono
Laboratories Inc., including Chief Medical Officer and Senior Vice President of Research and
Development. Prior to Serono, he served as a scientific advisor to Immunogen Inc., and held
clinical and teaching positions at the Dana Farber Cancer Institute and Harvard Medical School. 

Dr. Breitmeyer received his M.D. and Ph.D. from Washington University School of Medicine, is board
certified in Internal Medicine and Oncology and is the author or co-author of numerous
publications.


Asger Aamund 
Chairman of the Board


Contact
Anders Hedegaard, President & CEO. Phone +45 23 20 30 64

About Bavarian Nordic
Bavarian Nordic is a vaccine-focused biotechnology company developing and producing novel vaccines
for the treatment and prevention of life-threatening diseases with a large unmet medical need. The
company's pipeline targets cancer and infectious diseases, and includes ten development programs.
In oncology, the company's lead program is PROSTVAC(R), a therapeutic vaccine candidate for
advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 trial and is being
developed under a collaboration agreement with the National Cancer Institute. In clinical Phase 1
and Phase 2 trials, PROSTVAC(R) has been tested in nearly 600 patients. In infectious diseases,
the company's lead program is IMVAMUNE(R), a non-replicating smallpox vaccine candidate that is
being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a
contract with the U.S. Government. For more information, visit www.bavarian-nordic.com
http://www.bavarian-nordic.com 

Forward-looking statements 
This announcement includes "forward-looking statements" that involve risks, uncertainties and
other factors, many of which are outside of our control that could cause actual results to differ
materially from the results discussed in the forward-looking statements. Forward-looking
statements include statements concerning our plans, objectives, goals, future events, performance
and/or other information that is not historical information. We undertake no obligation to
publicly update or revise forward-looking statements to reflect subsequent events or circumstances
after the date made, except as required by law.

201303uk http://hugin.info/100065/R/1676599/546505.pdf 


----------------------------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Bavarian Nordic A/S via Thomson Reuters ONE


HUG#1676599

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.